The Cancer Letter

Inside information on cancer research and drug development

In Brief

Emory Winship receives $24.8M from ARPA-H for mRNA therapeutics project

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Winship Cancer Institute of Emory University received a three-year, $24.8 million cooperative agreement from the Advanced Research Projects Agency for Health to lead the CUREIT program: “Curing the Uncurable via RNA-Encoded Immunogene Tuning.” 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

mRNA biomarkers and AI algorithm detect colorectal cancer

Topline results from a pooled clinical study show that Mainz Biomed’s portfolio of proprietary novel gene expression (mRNA) biomarkers can be used in a next generation version of the company’s colorectal cancer screening tool. The study included new patients and subjects from Mainz Biomed’s ColoFuture (Europe) and eAArly DETECT (U.S.) clinical trials. The topline results confirm the positive efficacy results previously reported with a sensitivity for colorectal cancer of 92% with a specificity of 90% and a sensitivity for advanced adenoma of 82%, the company said.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account